Skip to main content

Tanzeum FDA Approval History

FDA Approved: Yes (First approved April 15, 2014)
Brand name: Tanzeum
Generic name: albiglutide
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Diabetes, Type 2

Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.

Development timeline for Tanzeum

Apr 15, 2014Approval FDA Approves Tanzeum (albiglutide) to Treat Type 2 Diabetes
Aug  2, 2013Regulatory Update: Albiglutide US PDUFA Date Extended by Three Months
Jan 14, 2013GSK Announces Submission of Albiglutide BLA to the US FDA for the Treatment of Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.